StockNews.AI
MXCT
StockNews.AI
131 days

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

1. MaxCyte will release Q1 2025 financial results on May 7. 2. A conference call will follow the earnings release at 4:30 p.m. ET. 3. MaxCyte focuses on advancing cell therapies with its ExPERT platform. 4. Their technology supports the cell therapy market's discovery and commercialization. 5. Registration for the call is required, indicating high investor interest.

4m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings reports can affect stock price, but expectations may be priced in already. Past earnings reports often show limited movement unless surprises occur.

How important is it?

The earnings call may provide insights into MXCT's growth potential and market performance, influencing investor sentiment.

Why Short Term?

The earnings report will create immediate market reactions but may have limited lasting impact without substantial news.

Related Companies

ATNMEDITCRIS
April 10, 2025 02:00 ET  | Source: MaxCyte, Inc ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/. About MaxCyte At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@maxcyte.com US Media RelationsSpectrum ScienceJordan Vinesjvines@spectrumscience.com +1 540-629-3137 Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@icrhealthcare.com

Related News